Regulatory approval

Published by the European Medicines Agency. Superseded

JEMPERLI is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.

This is written in the approval document.

Citation

GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised June 2025. Accessed August 29, 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description
2024-10-20	Van Allen lab	Adding EMA approvals for use to database
2023-12-07	European Medicines Agency	Indication received approval from the European Commission.